# Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04665206/  
OnCo record `nct04665206` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Osimertinib, Pemetrexed, Carboplatin in mesothelioma, run by Vivace Therapeutics, Inc, now recruiting.

## Summary

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04665206 by Vivace Therapeutics, Inc, with 434 participants planned, started 2021-03-24 and due to reach its primary completion in 2029-11-02. Interventions recorded: VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin. Conditions listed: Solid Tumor, Adult, Mesothelioma, NSCLC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04665206
- Phase: 1/2
- Setting: Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Vivace Therapeutics, Inc
- Enrolled: 434

## Sources

- ClinicalTrials.gov NCT04665206: https://clinicaltrials.gov/study/NCT04665206

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct04665206.json